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Hepatitis E virus (HEV) is a viral pathogen transmitted primarily via fecal-oral route. In
humans, HEV mainly causes acute hepatitis and is responsible for large outbreaks of
hepatitis across the world. The case fatality rate of HEV-induced hepatitis ranges from
0.5 to 3% in young adults and up to 30% in infected pregnant women. HEV strains
infecting humans are classified into four genotypes. HEV strains from genotypes 3 and 4
are zoonotic, whereas those from genotypes 1 and 2 have no known animal reservoirs.
Recently, notable progress has been accomplished for better understanding of HEV
biology and infection, such as chronic HEV infection, in vitro cell culture system, quasi-
enveloped HEV virions, functions of the HEV proteins, mechanism of HEV antagonizing
host innate immunity, HEV pathogenesis and vaccine development. However, further
investigation on the cross-species HEV infection, host tropism, vaccine efficacy, and
HEV-specific antiviral strategy is still needed. This review mainly focuses on molecular
biology and infection of HEV and offers perspective new insight of this enigmatic virus.
Keywords: hepatitis E virus, HEV, HEV biology, viral proteins of HEV, HEV infection, HEV vaccine
INTRODUCTION
Hepatitis E virus (HEV) is a positive-sense, single-stranded RNA virus, and is classified in the
genus Orthohepevirus, the family Hepeviridae (Smith et al., 2014). The HEV-caused hepatitis E
is generally a self-limiting disease with a case fatality rate from 0.5 to 3% in young adults but
up to 30% in infected pregnant women in their third trimester of gestation (Jameel, 1999; Nan,
2014). World Health Organization (WHO) estimates that there are 20 million infections with over
3 million symptomatic cases and 56,600 deaths annually across the world (WHO, 2015). HEV is
primarily transmitted via fecal-oral route. HEV infection was previously thought to be a public
health problem only for the developing countries. Indeed, hepatitis E is highly endemic in East
and South Asia, as well as Africa according to the WHO (WHO, 2015). HEV strains infecting
humans are classified into four genotypes. HEV strains from genotypes 3 and 4 are zoonotic,
whereas, those from genotypes 1 and 2 have no known animal origin. Discovery of HEV from
swine and other species suggests that genotypes 3 and 4 HEV has a wide host range (Christensen
et al., 2008; Dalton et al., 2008; Meng, 2013; Pavio et al., 2015). Currently, hepatitis E is frequently
recognized in industrialized countries, where it was not thought to be endemic (Kwo et al., 1997;
Erker et al., 1999; Schlauder et al., 1999; Worm et al., 2000; Kabrane-Lazizi et al., 2001; Mizuo et al.,
2002; Sadler et al., 2006). Moreover, along with isolation of HEV from the pig, chicken, mongoose,
rabbit, rat, ferret, bat, fish, and deer (Meng et al., 1997; Haqshenas et al., 2001; Li et al., 2005c;
Cossaboom et al., 2012; Smith et al., 2014), cross-species infection of HEV from animal reservoirs
to humans is thought to be the major cause of sporadic cases of hepatitis E in the industrialized
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countries (Pavio et al., 2015). Although previously thought to
only cause acute infections, HEV is found in chronic infections
reported both in immune compromised and immunocompetent
individuals (Hoofnagle et al., 2012; Grewal et al., 2014).
In addition, extrahepatic manifestations, such as neurological
disorders and kidney injury in HEV infected patients have been
documented (Kamar et al., 2011, 2012b; van Eijk et al., 2014;
Dalton et al., 2016; Geng et al., 2016). Taken together, current
knowledge for HEV implies a significant underestimation of HEV
infection as a public health concern. In the following sections,
recent progress in HEV biology, functions of viral proteins, cell
culture system, epidemiology, viral pathogenesis, treatment, and
vaccine development are reviewed and perspective new insights
are discussed.
HEV BIOLOGY
Hepatitis E was initially designated as enterically transmitted
non-A, non-B hepatitis (ET-NANBH) due to similar clinical
presentations to hepatitis A and B in patients, but the prospective
causative agent was initially unknown (Balayan et al., 1983).
Early research implied that an RNA virus was the potential
pathogen for the ET-NANBH. By analysis of a cDNA library from
infectious bile sample, a portion of a highly conserved RNA-
dependent RNA-polymerase (RdRp) motif, commonly found in
RNA viruses, was identified (Reyes et al., 1990). This new virus
was designated as HEV, which was responsible for the outbreak
of ET-NANBH.
The complete sequence of HEV genome was published 1 year
later (Tam et al., 1991). Sequence analysis indicated that HEV
contains a 7.2 kb single-stranded positive-sense RNA genome,
which is capped and poly-adenylated (Ahmad et al., 2011). There
are three partially overlapped open reading frames (ORFs) in
an order of sequences encoding non-structural proteins (NSPs)
followed by structural protein (Tam et al., 1991; Tsarev et al.,
1992; Figure 1). HEV ORF1 encodes a non-structural polyprotein
that consists of replicase proteins needed for HEV replication.
ORF2 encodes the capsid protein, which is the major structural
protein of the HEV virions, which are non-enveloped particles
of 32–34 nm in diameter (Mori and Matsuura, 2011). ORF3
encodes a small multifunctional protein with a molecular mass of
13 kDa (VP13). There are also short untranslated regions (UTRs)
in both the 5′ and 3′-end of the genome. Recently, an ORF4
was identified from genotype 1 HEV solely (Nair et al., 2016;
Figure 1). Expression of ORF4 is cap-independent and driven
by a putative IRES-like element between 2701 and 2787 nt of the
HEV genome (Nair et al., 2016).
The ORF1 of HEV can be translated directly from the genomic
RNA, whereas ORF2 and ORF3 are translated soly from the
sub-genomic RNA in alternative frames (Graff et al., 2006).
In an earlier report, three RNA species were detected in liver
tissue of experimentally infected macaques, with sizes of 7.2,
3.7, and 2 kb (Tam et al., 1991). The 3.7 and 2 kb RNA species
were thought to be sub-genomic RNAs for translation of ORF2
and ORF3, respectively. However, a later study in Huh7 cells
only identified one capped 2.2 kb sub-genomic RNA, which is
a bicistronic mRNA for translation of both ORF2 and ORF3
(Graff et al., 2006). Transcription of this sub-genomic RNA
initiates at nucleotide position 5122 in the Sar55 strain, which
is located downstream of the first two methionine codons of the
initially presumed ORF3. The same conclusion was drawn from
another in vitro study of genotype 3 HEV infection in PLC/PRF/5
hepatoma cells (Ichiyama et al., 2009). The HEV genome contains
two cis-reactive elements (CREs) that are essential for the viral
replication (Cao et al., 2010; Parvez, 2015b). The first CRE
overlaps the 3′ end of ORF2 and the 3′ UTR and is essential for
HEV replication. The second CRE locates in the intergenic region
of the HEV genome and forms a stem–loop structure that may be
the promoter for synthesis of the 2.2-kb subgenomic RNA (Cao
et al., 2010).
GENOTYPES OF HEV STRAINS
Hepatitis E virus was initially classified as a member of the
Caliciviridae family. However, sequence analysis of HEV ORF1
indicated no similarity to Caliciviruses, or other picorna-like
viruses. On the other hand, there is limited but significant
similarity to the alphavirus-like superfamily of RNA viruses,
specifically, the rubella virus (Berke and Matson, 2000).
Consequently, HEV was classified into the family Hepeviridae
(Berke and Matson, 2000; Emerson and Purcell, 2003).
Although HEV strains are highly diverse and heterogenic, only
one serotype of HEV exists. Classification of HEV strains is under
transition due to the different criteria used (Smith et al., 2013,
2014). Recently, a new proposal for the classification of the family
Hepeviridae was published (Smith et al., 2014). In this proposal,
the family Hepeviridae contains two genera: Orthohepevirus
(all mammalian and avian HEV isolates) and Piscihepevirus
(trout HEV; Table 1). Within the genus Orthohepevirus, four
different species (A, B, C, D) are designated to include isolates
from different hosts (Smith et al., 2014). All four previously
recognized HEV genotypes (1–4) that infect humans belong to
the Orthohepevirus A virus (Smith et al., 2014).
The previously recognized HEV genotypes 1–4 classification
system was based on complete genomic sequences (Lu et al.,
2006). HEV genotype 1 is the most conserved among the four
genotypes. There is only one full-length genotype 2 sequence
available (Smith et al., 2016). Both HEV genotypes 1 and 2 are
restricted to humans with no known animal reservoirs, whereas
genotypes 3 and 4 are zoonotic with an expanded host range
(Table 1; Meng, 2010; Ahmad et al., 2011). Therefore, genotypes 3
and 4 HEV strains are highly diverse (Lu et al., 2006; Smith et al.,
2014). Since the constant discovery of new HEV or HEV-related
isolates from rabbit, rat, ferret, bat, moose, farmed mink, camel,
and wild boar (Lorenzo et al., 2007; Zhao et al., 2009; Johne et al.,
2010; Geng et al., 2011; Takahashi et al., 2011; Drexler et al., 2012;
Raj et al., 2012; Krog et al., 2013; Lin et al., 2014; Woo et al., 2014),
four genotypes are no longer satisfying classification of expanding
HEV isolates. In the new classification system, some HEV strains
from wild boars in Japan with unique viral nucleotide sequences
are designated as genotypes 5 and 6, while HEV from camel is
classified as genotype 7 of Orthohepevirus A (Smith et al., 2014).
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FIGURE 1 | Schematic illustration of hepatitis E virus (HEV) genome, subgenomic RNA, and ORFs. ORF1 (nt 26–5107) is labeled above the genomic RNA
box. ORF2 (nt 5145–7127) and ORF3 (nt 5131–5475) are encoded by the same subgenomic RNA. The newly identified ISRE like sequence (nt 2701–2787) and
ORF4 (nt 2835–3308) which are overlapped with ORF1 are listed as well. Moreover, the numbers above or below the RNA boxes indicate nucleotide numbers of the
cDNA of HEV Sar55 (GenBank accession number AF444002) genomic RNA.
The genotypes that infect humans include 1, 2, 3, 4, and 7
(Table 1; Smith et al., 2016).
Hepatitis E virus-like virus isolated from avian species is called
avian HEV, which shares less than 50% nucleotide identity but
common antigen epitopes in the capsid protein with mammalian
HEV (Haqshenas et al., 2001, 2002; Huang et al., 2004). Currently,
avian HEV is classified into the species Orthohepevirus B (Smith
et al., 2014). HEV strains from rat, ferret and bat are classified
into the species of Orthohepevirus C and D, respectively (Smith
et al., 2014). The cutthroat trout virus (CTV) is identified as an
HEV-like virus in retrospective studies. CTV shares even lower
sequence identity with mammalian and avian HEV and is now
classified as a member of the genus Piscihepevirus (Batts et al.,
2011; Smith et al., 2014).
For the four genotypes (1–4) of HEV infecting humans, there
are differences in their geographic distributions. Genotype 1
HEV mainly includes strains from Asia and Africa including the
Sar55 isolate, while genotype 2 contains a Mexican strain and
TABLE 1 | Hepatitis E virus (HEV) genotypes, natural hosts, and zoonotic infection to humans.
Genus Species Genotype Natural hosts Infection to humans
Orthohepevirus Orthohepevirus A 1 Human Yes
2 Human Yes
3 Human, pig, rabbit, deer, mongoose, wild boar Yes
4 Human, pig, yak, wild boar Yes
5 Wild boar Unknown
6 Wild boar Unknown
7 Camel Yes
Orthohepevirus B Chicken No
Orthohepevirus C C1 Rat No
C2 Ferret No
Orthohepevirus D Bat No
Piscihepevirus Piscihepevirus A Trout No
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variants from Africa. Genotypes 3, including human and swine
HEV, is mainly found in the industrialized countries (Purcell
and Emerson, 2008). The genotype 4 is previously thought to
be found only in China (Purcell and Emerson, 2008), however,
recent reports show that genotype 4 HEV strains are also isolated
in other countries, including India, Indonesia, Japan, Vietnam,
Spain, France, and Italy (Okamoto, 2007; Midgley et al., 2014;
Lapa et al., 2015). For details about molecular epidemiology and
viral evolution of HEV, please refer to the article by Purdy and
Khudyakov (2011).
VIRAL PROTEINS OF HEV AND THEIR
FUNCTIONS
ORF1-Encoded Polyprotein
The ORF1 is the largest ORF in the HEV genome and has
5082 nt in length according to the Sar55 strain (Tsarev et al.,
1992; Emerson et al., 2001). It starts at the 5′ end of the
genome after a 25 nt non-coding region and can be translated
directly from the HEV genome. ORF1 encodes a 1693 amino
acid (aa) polyprotein, which is needed for HEV replication.
Bioinformatics analysis for the protein sequence encoded by
ORF1 found eight putative domains according to their similarity
to counterparts in the other viruses (Koonin et al., 1992).
Moreover, the ORF1 sequence is highly related to the group of
Rubi-like viruses including Rubivirus, Betatetravirus, Benyvirus,
and Omegatetravirus (Koonin and Dolja, 1993; Liu et al., 2009).
These functional domains include methyltransferase domain
(Met), Y domain (Y), papain-like cysteine protease (PCP or
PLP), hypervariable region (HVR), proline-rich region (Pro), X
domain, helicase domain (Hel) and RdRp (Figure 2). In recent
publications, the proline-rich region is frequently named together
with HVR as the HVR.
The current data are conflicting about whether the HEV ORF1
product functions as a single polyprotein or needs to be further
processed into smaller units by viral or cellular proteases (Ansari
et al., 2000; Ropp et al., 2000; Sehgal et al., 2006; Suppiah et al.,
2011; Perttila et al., 2013). One study using a vaccinia-derived
expression system demonstrated that the ORF1 polyprotein could
be cleaved by the PCP within it (Ropp et al., 2000). More
than 10 years after that publication, the same group showed a
lack of processing of the ORF1 polyprotein in HEK293T cells
(Suppiah et al., 2011). Two fragments were found in another
study on in vitro translation of full-length ORF1, but they
were not observed in pulse-chase assay in human cells and
their production was not dependent on the predicted protease
domain in ORF1 product (Perttila et al., 2013). Furthermore,
in Escherichia coli and a cell-free system based on HepG2 cells,
ORF1 was expressed as a 186 kDa protein without further
processing detected (Ansari et al., 2000).
On the other hand, other studies demonstrated contrasting
results. Transfection of HepG2 cells with in vitro transcribed
RNA from HEV cDNA produced cleaved products with sizes
of 35, 38, and 36 kDa for the Met, Hel, and RdRp domains,
respectively (Panda et al., 2000). Another study focusing on
the analysis of the ORF1 functional domains also observed
proteolytic processing of the HEV ORF1 fragment in insect
cells (Magden et al., 2001). In a later study, the ORF1 product
expressed in insect cells by baculovirus expression system
was shown to exist as smaller fragments and this proteolytic
processing could be inhibited by E-64d, a cell-permeable cysteine
protease inhibitor (Sehgal et al., 2006). A recent publication
reported that the refolded PCP domain expressed in E. coli is
able to process ORF1 polyprotein in vitro (Paliwal et al., 2014).
Moreover, based on an HEV-Sar55 replicon system in S10-3
cells (a subclone of Huh7 cells with improved HEV replication;
Graff et al., 2006), the putative catalytic aa residues in the ORF1
protease domain are indispensable for HEV replication (Parvez,
2013). Overexpression of ORF1 from HEV Sar55 strain in S10-3
cells also resulted in cleaved products (Parvez, 2013).
Thus, despite the lack of conclusive data, the majority of
studies so far are in favor of the polyprotein proteolysis. The
cleaved ORF1 products could be possibly detected in the HEV-
infected cells if effective and specific antibodies against the
domains are available. A recent study employing yeast two
hybrid (Y2H) demonstrated intraviral interactome within the
domains from ORF1, further supporting the proteolysis of ORF1
polyproteins (Osterman et al., 2015). Moreover, ORF1 could be
a determining factor for host tropism as a recombinant HEV
harboring ORF1 of a genotype 4 HEV strain and the rest genome
from genotype 1 strain replicates in transfected porcine kidney
cells (Chatterjee et al., 2016). Therefore, ORF1 products involve
in determination of HEV host tropism and should be further
investigated. It is possible that proline rich region or HVR may
be involved in host tropism determination since other domains
are more conserved among the four HEV genotypes.
Met Domain
The Met domain is the first one at the N-terminus of the
ORF1-encoded polyprotein. As the HEV genome is capped
and the capping is crucial for its infectivity, a viral-specific
FIGURE 2 | Schematic illustration of putative domains in ORF1 polyprotein. Met: Methyltransferase domain; Y: Y domain; PCP: papain-like cysteine protease;
HV: hypervariable region; Pro: proline-rich domain; X: X-domain; Hel: helicase; RdRp: RNA-dependent RNA polymerase. The numbers above the box indicate amino
acid residues of ORF1-encoded polyprotein of Sar55 strain.
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methyltransferase was expected (Emerson et al., 2001; Zhang
et al., 2001). Based on sequence analysis, the region in aa
residues 60–240 was assumed to be a putative methyltransferase
(Koonin et al., 1992). The HEV Met domain is similar to that
of Tricornaviruses, which belong to the alpha-like supergroup of
RNA viruses (van der Poel et al., 2001). There are an invariant
His residue, an AspXXArg signature and an invariant Tyr residue
in methyltransferase motifs I, II, and IV, respectively (Rozanov
et al., 1992). Expression of HEV ORF1 cDNA (aa residues 1–979)
in insect cells yields a 110 kDa protein (P110), along with a
80 kDa protein that is believed to be the proteolytic product of
P110 (Magden et al., 2001). In vitro assays shows that the P110
possesses guanine-7-methyltransferase and guanylyl transferase
activity (Magden et al., 2001).
Y Domain
The second domain after the methyltransferase is the Y domain,
which is assumed to start from aa residue 216 and ends at aa 442.
It is highly similar to that of the rubella virus (Koonin et al., 1992).
Currently, there is no information available for the function of
this Y domain in either HEV or the rubella virus.
PCP Domain
Papain cysteine protease domain is downstream of the Y domain.
The PCP domain demonstrates moderate similarity to the
protease domain in the rubella virus (Koonin et al., 1992).
In the rubella virus, the PCP domain is responsible for the
proteolytic processing of its NSP (Marr et al., 1994). Mutation
of the catalytic residue within the PCP (Cys1152) abolishes its
protease activity and results in inhibition of the NSP processing.
It is also involved in trans and cis cleavage of the rubella virus
NSP (Liang et al., 2000). However, regarding the function of
the HEV PCP domain, the current data are incomplete and
controversial.
In the vaccinia-mediated ORF1 expression system, mutation
of the putative catalytic core (Cys483) of HEV PCP had no effect
on proteolytic processing of the ORF1 product (Ropp et al.,
2000). Another putative catalytic site of His590 in PCP is not
conserved among different HEV strains. Later studies showed
controversial data for the processing of the HEV ORF1 product
(Ansari et al., 2000; Ropp et al., 2000; Sehgal et al., 2006; Suppiah
et al., 2011). This leads to the speculation that whether HEV
PCP is a real cysteine protease. Recently, Parvez demonstrated
that the mutation of six cystine residues (C457A, C459A, C471A,
C472A, C481A, C483A) and three histidine residues (H443L,
H497L, H590L) in the PCP domain completely abolished HEV
RNA replication in a Sar55-based replicon system in S10-3 cells.
Notably, of these essential Cys and His residues, C483 and
H590 were previously predicted as putative catalytic residues in
the PCP domain (Parvez, 2013). Furthermore, the PCP domain
expressed in the E. coli C43 strain (resistant to toxic protein
expression) possesses protease activity (Paliwal et al., 2014). The
purified protein cleaves both HEV ORF1 and ORF2 products that
are in vitro translated. Protease inhibitor assay indicates the HEV
PCP domain is a chymotrypsin-like protease (Paliwal et al., 2014).
This observation suggests that HEV PCP is a real protease for
HEV ORF1 polyprotein processing.
In recent years, the connection between ubiquitination and
innate immunity signaling has been demonstrated (Zeng et al.,
2009; Mao et al., 2010; Liu et al., 2013), and the antiviral function
of some ubiquitin-like molecules, such as interferon-stimulated
gene 15 (ISG15) and small ubiquitin-like modifier (SUMO), has
been described (Liu et al., 2013). Some studies indicate that viral
coded cysteine proteases possess deubiquitinase activity to inhibit
host innate immunity, such as arterivirus papain-like protease 2
(van Kasteren et al., 2013) and PCP from porcine reproductive
and respiratory syndrome virus (PRRSV; Li et al., 2010; Sun
et al., 2010). Similar research performed on the HEV PCP domain
suggests that it acts as an antagonist to ISG15 function to inhibit
host innate immunity when expressed together with Met as the
Met-PCP protein (Karpe and Lole, 2011). Moreover, study from
our laboratory demonstrated that the PCP domain from HEV
genotype 1 Sar55 strain is able to inhibit ubiquitination of RIG-I
and TBK1, therefore resulting in the inhibition of RIG-I mediated
signaling in innate immune responses (Nan et al., 2014b).
HVR Domain
Between the PCP domain and the X domain, there are HVR and
Pro domains. These two regions were first named as HVR due to
the extreme divergence in sequence between nt 2011 and 2325
(corresponding to residues aa 662–766) when the HEV Sar55
was compared with two other strains (Tsarev et al., 1992). In a
later study, aa 712–778 in this region were designated a proline-
rich region, which could be found in rubella virus as well. It
was also considered to serve as a hinge between the X domain
and its upstream domains because multiple proline residues in a
protein or polypeptide may result in an unstable tertiary structure
(Koonin et al., 1992; Tsai et al., 2001; Dosztanyi et al., 2006;
Dunker et al., 2008). The length and sequence of HVR and Pro is
highly variable among different HEV strains (Pudupakam et al.,
2009; Smith et al., 2013).
Currently, there is some confusion regarding the nomen-
clature of those two regions. Some of the recent publications
designated the region of aa 712–778 as the hypervariable domain,
which was originally referred to proline-rich region and left
out the immediately upstream domain (aa 592–711; Pudupakam
et al., 2009, 2011), whereas others still designate the aa 712–778
as the proline-rich region (Purdy, 2012). Current research mainly
focuses on the Pro region and pays less attention to the upstream
HVR domain. As a result, the function of HVR is unknown.
However, data gained from the rubella virus shows that deleting
part of the HVR domain along with part of the Pro region renders
the mutant non-viable (Tzeng et al., 2001).
Pro Domain
The Pro domain is considered to be an intrinsically disordered
region (IDR) with flexibility for insertion and deletion (Purdy,
2012; Purdy et al., 2012). Data from its counterpart in the rubella
virus indicates that this region is not required for viral replication
(Tzeng et al., 2001). As expected, deletion and mutation of
this region in HEV indicates that it is not required for viral
replication and infectivity, but it plays a role in replication
efficiency in vitro (Pudupakam et al., 2009, 2011). It was also
demonstrated that the Pro domain is interchangeable between
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genotypes with genotype-specific differences (Pudupakam et al.,
2011). More interestingly, a remarkable HEV strain Kernow-C1,
which was originally isolated from an HIV-positive patient with
chronic HEV infection, contains an insertion of a 174 nt gene
fragment of human ribosomal protein S17 in the Pro region
(Shukla et al., 2011). This recombinant virus was adapted in
culture cells and is able to propagate in cells from different
species. It was speculated that insertion of the S17 fragment
occurred in the host but was selected in cultured cells. This
speculation needs further verification as direct detection of the
inserted fragment from the host sample was not successful.
Experimental insertion of the S17 fragment into the Pro domain
of the Sar55 strain also generated a viable chimeric virus (Shukla
et al., 2011). The S17 sequence insertion in HEV correlates
with novel nuclear/nucleolar trafficking capabilities to the ORF1
protein of HEV Kernow C-1 P6 and the enhanced replication of
this strain (Kenney and Meng, 2015a,b).
Although the Pro domain is considered highly diverse, some
motifs are found in the IDR. Based on computer analysis and
comparison with other IDRs, Purdy et al. identified several linear
motifs (LMS), including two protease cleavage sites, three ligand
binding sites and two kinase phosphorylation sites across all
four genotypes (Purdy et al., 2012). The putative protein–protein
interactions of the Pro domain were proposed in the same report
as well, but need experimental verification. Nevertheless, this
report provides some assumptions about the disorder-to-order
state of the Pro domain. In another study, alignment of the Pro
domain from different genotypes indicated the sequence is more
conserved in genotypes 1 and 2 than genotypes 3 and 4 (Purdy,
2012). Adaptation to a wide host range for genotypes 3 and 4 is
a possible reason. The authors also assessed the diversity of the
Pro domain due to the higher rate of substitutions at the first
and second codon positions, leading to a shift in translation to be
more proline, alanine, serine, and threonine rather than histidine,
phenylalanine, tryptophan, and tyrosine. This pattern matches
the aa usage in proline-rich IDRs (Purdy, 2012). Furthermore,
the C-terminus of this domain can tolerate more mutations than
the N-terminus. Recently, the heterogeneity of the Pro and X
domains is implicated in HEV persistence, which was revealed
in an investigation into the association between the genetic
heterogeneity of HEV quasispecies in ORF1 and the outcome
of infection in solid-organ transplant patients (Lhomme et al.,
2014).
X Domain
The X domain is located immediately downstream of the Pro
domain. In HEV, its function is unknown. The HEV X domain
homologs in other viruses such as rubella virus, alpha virus
and coronavirus, are commonly identified as domain flanking
the PCP domain (Gorbalenya et al., 1991; Koonin et al., 1992).
It is also known as macro domain, due to its similarity with
non-histone domain of the histone macroH2A. Macro domain
has been identified in a variety of bacterial, archaeal, and
eukaryotic organisms (Pehrson and Fried, 1992; Pehrson and
Fuji, 1998).
Early studies of the human macro domain indicate that it is
enriched in inactive mammalian X chromosomes, suggesting a
role in gene silencing and inactivation (Costanzi and Pehrson,
1998). The macro domain inhibits transcription and binds to
the transcription activator NF-κB (Perche et al., 2000; Angelov
et al., 2003). Crystal structure analysis identifies a DNA binding
motif in the macro domain, suggesting that it might interact
with nucleic acids (Allen et al., 2003). A biochemical functional
analysis indicates that the macro domain is involved in the
downstream processing of ADP-ribose 1′′-phosphate, a side
product of cellular pre-tRNA splicing (Martzen et al., 1999).
Furthermore, the macro domain is found in association with
proteins involved in poly(ADP-ribose) polymerization, ADP-
ribosylation and ATP-dependent chromatin remodeling (Aguiar
et al., 2005).
Information about the function of viral macro domains
is limited. ADP-ribose 1′′-phosphatase activity has been
demonstrated in the macro domain from coronavirus (Martzen
et al., 1999; Putics et al., 2005, 2006; Saikatendu et al., 2005).
Crystal structure analysis and in vitro assays on the macro
domain of the SARS virus indicate that the viral macro domain
has relatively poor ADP-ribose 1′′-phosphohydrolase activity,
but can bind free ADP-ribose and poly(ADP-ribose) efficiently
(Egloff et al., 2006). In another report, the macro domains from
Semliki Forest virus, HEV, SARS virus and yeast were compared
with the human macro domain (Neuvonen and Ahola, 2009).
The viral macro proteins bind poly (ADP-ribose) and poly
(A), but have a low affinity for monomeric ADP-ribose. This
implies that viral macro domains are functionally different
from human homolog and may participate in cellular pathways
involving RNA rather than ADP-ribose derivatives. However, a
recent study shows that viral macro domains (HEV, coronavirus,
and venezuelan equine encephalitis virus) can reverse protein
ADP-ribosylation by acting on ADP-ribosylated substrates
through the hydrolytic activity of their macro domains (Li et al.,
2016). Furthermore, other studies indicate that the expression
of viral macro domain in liver cells inhibits apoptosis since it is
functionally related to poly(ADP-ribose) polymerase-1 (PARP-1;
Allen et al., 2003; Chen et al., 2009), suggesting a role in apoptosis
during viral infection. Recently, a highly conserved “glycine-
triad” (Gly815-Gly816-Gly817) was identified downstream
of the macro domain of HEV, which is homologous to the
rubella virus protease-substrate (G1299-G1300-G1301; Parvez,
2013). Mutagenesis study indicates that G816V and G817V
mutations in the macro domain are lethal for Sar55 replication in
S10-3 cells. Further analysis identified the N-terminus residues
Asn806, Asn809, His812, Gly815-Gly816-and Gly817 formed
a potential catalytic-site homolog of Coronavirus ADP-ribose-
1′-monophosphatase, which has essential role in viral replication
(Parvez, 2015a). As mentioned above, a recent report suggests
that the quasispecies heterogeneity in the macro domain might
facilitate HEV persistence in solid-organ transplant patients
(Lhomme et al., 2014). Study from our laboratory demonstrates
that X domain of HEV Sar55 strain inhibits the phosphorylation
of IRF3, which is a key transcription factor for type I IFN
induction (Nan et al., 2014b). Moreover, except interacting with
light chain subunit of human ferritin and inhibiting ferritin
secretion, the X domain interacts with HEV Met and VP13
(Anang et al., 2016; Ojha and Lole, 2016).
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Helicase Domain
The RNA helicase domain is downstream of the X domain. It is
encoded by many positive-stranded RNA viruses and is essential
for their replication (Kadare and Haenni, 1997). Helicases are
motor proteins that are able to unwind nucleic acid strands by
using energy from ATP hydrolysis (Kadare and Haenni, 1997).
Helicases can be divided into six superfamilies (SF1-6; Singleton
et al., 2007). RNA virus coded helicases are mainly classified into
SF1 and SF2. Helicases SF1 and SF2 contain seven signature
motifs (I, Ia, II, III, IV, V, and VI) that form the core of the
enzyme (Kadare and Haenni, 1997). The HEV helicase belongs to
helicase superfamily SF1 and is proposed to possess both NTPase
and RNA unwinding activities (Koonin et al., 1992; Kadare and
Haenni, 1997). In vitro experiments demonstrate that the HEV
helicase purified from E. coli expression has both of the activities.
It drives the hydrolysis of rNTPs but also dNTPs at a lower
efficiency, as well as unwinds RNA duplexes with 5′ overhangs
(Karpe and Lole, 2010a). RNA 5′-triphosphatase activity has also
been observed in the HEV helicase domain, which is proposed
to function along with methyltransferase for catalyzing RNA
capping (Karpe and Lole, 2010b). Recently, a mutagenesis study
on HEV helicase demonstrated that motifs I, IV, and VI are
dispensable, while motifs I and III are crucial and unique for
HEV helicase function (Mhaindarkar et al., 2014). A recent study
shows that a V239A substitution in the helicase domain of a swine
HEV strain is potentially associated with increased virulence
(Ward et al., 2015). However, no human infection was reported
to be associated with this strain.
RdRp Domain
The last domain of HEV ORF1 polyprotein is the RdRp. All
positive-stranded RNA viruses code an RdRp, which is necessary
for viral replication (O’Reilly and Kao, 1998). The RdRp from
all positive-sense RNA viruses are classified into three large
supergroups. All RdRp domains contain approximately 300
amino acid residues, with the central and C-terminal parts
showing high similarity between each other (Koonin, 1991).
RdRp from HEV belongs to supergroup III and has the highest
similarity to the domains in rubella virus and beet necrotic yellow
vein virus (BNYVV; Koonin et al., 1992). All eight conserved
motifs can be found in HEV RdRp, including an Mg2+ binding
sequence (GDD), which is essential for RdRp activity. The
purified HEV RdRp is able to bind the 3′ end of HEV RNA,
and needs two stem–loop structures at the 3′ end of the poly(A)
stretch for this binding (Agrawal et al., 2001). Expression of the
RdRp in mammalian cells as a GFP fusion protein indicates that
it localizes in endoplasmic reticulum (ER), which could be a
potential replication site for HEV (Rehman et al., 2008). Recent
studies indicate that the emergence of G1634R mutation in the
HEV RdRp is possibly due to ribavirin-induced mutagenesis and
is associated with treatment failure of ribavirin monotherapy in
solid-organ transplant patients (Debing et al., 2014b; Lhomme
et al., 2015; Todt et al., 2016).
The Capsid Protein Encoded by ORF2
The capsid protein is the major component of HEV virions.
ORF2 is 1983 nt in length beginning from 37 nt downstream of
ORF1 and ending at 65 nt upstream of the poly-A tail (Reyes
et al., 1993; Figure 1). The deduced full-length ORF2 product
has 660 aa residues with a predicted molecular mass of 72 kDa
(Robinson et al., 1998). Recombinant ORF2 protein can bind to
the 5′ region of HEV genome (Surjit et al., 2004). It was first
shown that the ORF2 product exists as an 88 kDa protein, which
carries N-terminal linked glycans and a potential ER-directing
signal about 15 aa from its N terminus (Jameel et al., 1996). This
88 kDa protein can be further processed and has the potential to
form non-covalent homodimers. A further study from the same
group demonstrated Asn310 in ORF2 product to be the major site
for glycosylation (Zafrullah et al., 1999; Figure 3). A mutagenesis
study indicated that the N-terminal signal peptide is required for
its cell surface expression via ER transition, but glycosylation of
the capsid protein is not required (Zafrullah et al., 1999).
Since glycosylation of the capsid protein in non-enveloped
viruses is not common, it is not known whether these
modifications have biological significance for HEV infection.
Mutations in the putative glycosylation sites (aa 137, aa 310,
aa 562) prevent formation of viral particles and infection of
rhesus macaques but without an effect on genome replication in
cells (Graff et al., 2008). Mutation in the first two glycosylation
sites prevents virion assembly, while mutation of the third site
allows virion particle formation and RNA encapsulation (Graff
et al., 2008). HEV particles released from cultured cells have a
lipid component (quasi-enveloped), which can be removed by
detergent treatment (Qi et al., 2015). The relationship between
glycosylation of ORF2 and lipid envelope of viral particles needs
to be clarified.
On the other hand, data acquired from studies using insect
cells provide a different conclusion regarding ORF2 expression
and processing. When expressed in insect cells, ORF2 product
can be an insoluble full length protein of about 72 kDa, and a
soluble form of 56.5 kDa, a processed product of the intact form
(McAtee et al., 1996). Another group shows that when ORF2
is expressed in SF9 cells, a 62 kDa product is detected while
lacking the first 111 aa residues of the putative ORF2 polypeptide
(Zhang et al., 1997). Further studies in two different insect cell
lines (SF9 and Tn5) show a soluble form of ORF2 product with a
molecular mass of 50 kDa, which lacks the first 111 aa and the
last 52 aa of ORF2 polypeptide but retains the ability to form
virus-like particles (VLPs; Li et al., 1997, 2005d). VLP assembly
is thought to involve dimer formation, and the C-terminus of
the recombinant ORF2 protein is believed to be responsible
for homo-oligomerization (Tyagi et al., 2001a; Xiaofang et al.,
2001; Li et al., 2005a). A 3.5-Å resolution crystal structure
obtained from HEV VLP indicates that the truncated HEV
capsid protein has three domains designated as S (shell, aa 129–
319), M (middle, aa 320–455), and P (protruding, aa 456–606;
Yamashita et al., 2009; Figure 3). The VLP is composed of 60
subunits of the truncated capsid protein, forming icosahedral 2,
3, and 5-fold axes (Yamashita et al., 2009). Mutational analyses
indicate that the protruding domain is involved in binding to the
susceptible cells and contains neutralization epitopes (Yamashita
et al., 2009). Moreover, the HEV VLP can be used as a delivery
system to display foreign epitopes on its surface (Xing et al.,
2011).
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FIGURE 3 | Schematic illustration of the domains of the HEV capsid protein encoded by ORF2. The numbers above the box and those in parentheses
indicate amino acid residues of the capsid protein. S domain: shell domain; M domain: middle domain; P domain: protruding Domain.
The ORF2 product expressed in insect cells is reactive with
anti-HEV antibodies (Tsarev et al., 1993). Genetic analysis
of ORF2 showed over 85% similarity among the four major
HEV genotypes in mammalian hosts (Mori and Matsuura,
2011). Amino acid alignment indicates that divergences are
mainly in the first 111 aa of the N terminus, which is not a
component of the virions (Mori and Matsuura, 2011). A study
manipulating a phage display system for overlapping peptides
and truncated ORF2 proteins maps the major neutralizing
domain to residues 458–607, which matches the location of the
P domain (Schofield et al., 2000; Meng et al., 2001; Zhou et al.,
2004). Both conformational and linear neutralizing epitopes have
been identified from the HEV capsid protein (Gu et al., 2015;
Tang et al., 2015).
These data provide valuable information for vaccine
development. The ORF2 truncated proteins generated by
baculovirus or bacterial expression systems have been tested in
clinical trials (Shrestha et al., 2007; Zhu et al., 2010). However, a
recent study that evaluated cross-protection against heterologous
HEV indicates that vaccination of pigs with truncated capsid
proteins derived from swine, rat and chicken HEV only
elicits partial protection against a genotype 3 mammalian
HEV (Sanford et al., 2012). Study of avian HEV capsid protein
indicates that the N-terminal 338 aa residues react with swine and
human anti-HEV sera (Wang et al., 2014b). Moreover, a recent
study suggests that antigenic composition and immunoreactivity
differed between HEV recombinant capsid proteins from
different genotypes (Behloul et al., 2015), which raises the
concerns about the efficacy of the current HEV subunit vaccine
marketed in China. On the other hand, experiments based on
the newly identified quasi-enveloped HEV particles indicate that
lipid membrane protects the virions from neutralizing antibodies
against the capsid protein (Yin et al., 2016).
Additionally, as a structural protein, the HEV capsid protein
has been found to interact with some cellular proteins and plays a
role in cell signaling. In one study, the capsid protein activates
the pro-apoptotic gene CHOP, and increases the expression of
HSP72, HSP70B and HSP40, and interacts with HSP72 (John
et al., 2011). In addition, the capsid protein interacts with
β-TRCP, a component of the ubiquitination complex that inhibits
IκBα ubiquitination-mediated NF-κB activation (Surjit et al.,
2012). However, these data are all based on overexpression of
ORF2 in mammalian cells, and need to be further verified in
whole virus infection.
ORF3-Encoded Protein VP13
The ORF3 is the smallest among the three ORFs of HEV and
overlaps with ORF2 by approximately 300 nt in a different
reading frame. However, it does not overlap with ORF1 (Graff
et al., 2006). The overlapping region with ORF2 (nt 5145–5475)
was found to be the most conserved region between the Sar55 and
BUR121 strains (Tsarev et al., 1992). An early study proposed that
ORF3 encodes a protein with 123 aa and comes from a different
subgenomic RNA other than that encoding ORF2 (Tam et al.,
1991). However, a later study based on an HEV replicon shows
that ORF3 is translated from the bicistronic subgenomic RNA
and initiates at the third AUG of the presumed ORF3 at nt 5131
for Sar55 and the product is a protein with 113 or 114 aa and
molecular size of 13 kDa (VP13), which is 9 aa shorter than the
earlier predicted version (Graff et al., 2006). This observation has
been confirmed by another study using a different HEV strain
(Huang et al., 2007).
Sequence analysis has indicated that VP13 is unique and
has no similarity to any other proteins known. It contains two
hydrophobic domains in its N-terminal half and two proline-rich
domains in its C-terminal portion (Kannan et al., 2009; Holla
et al., 2013). A phosphorylation site (Ser71) was identified in the
first proline-rich domain and can be phosphorylated by MAP
kinase (Zafrullah et al., 1997). Furthermore, two PSAP motifs
have been identified in genotype 3 VP13, with the first PSAP
motif located at aa 86–89 and the second at aa 95–98, whereas
genotypes 1, 2, and 4 have only one PSAP motif at aa 95–98
(Nagashima et al., 2011b). The second PSAP motif is needed for
HEV virion release. Interestingly, among the four genotypes that
infect humans, only genotype 1 vp13 has an additional proline-
rich region that contains a PXXP motif in aa 66–75, which
is linear and surface-oriented (Nan et al., 2014a,b, 2015). The
unique motif reacts with a genotype 1 VP13-specific monoclonal
antibody. This proline-rich region contains residues PMSPLR,
a typical motif (PXXPX+) (+ is either arginine or lysine, X
can be any aa) for class II SRC homology 3 (SH3) domains.
SH3 domains are known to bind to proline-rich sequences
containing a core PXXP motif flanked by a positively charged
residue (Baumann et al., 1998; Raeder et al., 1998). SH3 domains
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comprise of about 60 residues and proteins containing SH3
domains typically play a role in signaling pathways involved
in cell growth, differentiation and other regulatory functions
(Zarrinpar et al., 2003). The next proline-rich region spanning
aa 95–102 are RPSAPPLP, containing an additional residue than
the typical motif (+XXPXXP) for class I SH3 domains. But
interestingly only the PXXP motif in the second proline-rich
region is known to interact with SH3 domains (Korkaya et al.,
2001). The function of the PXXP motif in the first proline-rich
region (aa 66–75) of VP13 of genotype 1 HEV is unknown.
It might play a role in cellular signaling as proline-rich motifs
are also involved in interacting with other domains besides SH3
(Zarrinpar et al., 2003).
Although the full function of HEV VP13 has not been
defined yet, some studies have suggested that VP13 plays multiple
roles during HEV infection. Early studies focusing on VP13
antigenicity and epitope mapping demonstrated that the last 32
aa of VP13 are an immunodominant region, and a synthesized
peptide from that region is reactive with anti-HEV serum from
a recovered patient (Semiletov et al., 1995; Dement’eva et al.,
1997). However, another study mapping the T cell epitopes in
ORF2 and ORF3 products indicated that no T cell proliferation
was observed when cells were stimulated with peptides from
VP13 (Aggarwal et al., 2007). A recent study based on genotype
4 HEV shows that continuous amino acid motif, VDLP, at the
C-terminus of genotype 4 HEV VP13, is a core sequence of a
VP13 epitope (Wang et al., 2015). Although VP13 is dispensable
for viral replication in cultured cells (Emerson et al., 2006), it is
indispensable for HEV infection in vivo, implying an important
role for VP13 in host invasion (Graff et al., 2005; Huang et al.,
2007).
A yeast two-hybrid system is employed to screen for the
interaction partners for VP13. The VP13 can bind to inactive
mitogen-activated protein kinase (MAPK) phosphatase and lead
to activation of the MAPK (Kar-Roy et al., 2004), suggesting
that VP13 can modulate host gene expression since MAPK is
related to cell signaling and gene expression. Another study
shows that VP13 inhibits the nuclear translocation of STAT3
and down-regulates STAT3-mediated gene expression, such as
acute-phase response proteins (Chandra et al., 2008). The VP13
can also increase the expression of glycolytic pathway enzymes
by increasing the phosphorylation and transactivation activity of
p300/CBP (Moin et al., 2009). Furthermore, microarray analysis
of Huh7 cells with VP13 expression suggests that liver-specific
genes can be modulated, as VP13 is able to modulate the
phosphorylation of hepatocyte nuclear factor 4 (Chandra et al.,
2011).
The VP13 can also up-regulate mitochondrial voltage-
dependent anion channel genes, which can protect cells
from mitochondrial depolarization and death (Moin et al.,
2007). This result implies that VP13 is able to inhibit the
mitochondrial apoptosis pathway. The pro-survival role of VP13
is also demonstrated in another study showing VP13 delays
the trafficking and degradation of the activated hepatocyte
growth factor receptor to prolong endomembrane growth factor
signaling (Chandra et al., 2010). Additional interacting molecules
have been identified for VP13 by yeast two-hybrid screens,
including α-1-microglobulin, bikunin, and bikunin precursor
protein (AMBP), fibrinogen β chain and hemopexin (Tyagi et al.,
2004, 2005; Ratra et al., 2008, 2009). Moreover, a recent study
screening for intraviral protein interactions identified the Met,
PCP, X, Helicase, and RdRp domains as interacting partners for
VP13 as well (Osterman et al., 2015).
Besides yeast two-hybrid screens, overexpression of VP13
coding plasmid in mammalian cells was also employed to
elucidate the function of VP13. The VP13 associates with the
cytoskeleton fraction when expressed in cells, and deletion of
the N-terminal hydrophobic domain of VP13 abolishes this
association (Zafrullah et al., 1997). In a more detailed study,
GFP-tagged VP13 is found to interact with microtubules to form
a filamentous pattern in cells and modulate the microtubule
dynamics (Kannan et al., 2009). VP13 leads to an elevation of
acetylated α-tubulin, indicating increased microtubule stability
(Kannan et al., 2009). Since there are two hydrophobic domains
located in the N-terminus of VP13, truncation analysis indicated
that both the hydrophobic domains are required for its
association with the microtubules. Moreover, salt extraction
studies have suggested that the VP13-microtubule interaction
is electrostatic and motor protein dynein is needed for the
interaction (Kannan et al., 2009). An earlier study showed that
VP13 cannot be co-precipitated with tubulin by anti-tubulin
antibody (Zafrullah et al., 1997). These results suggest that
VP13 may associate with microtubules through interaction with
another protein. This microtubule-like distribution of VP13
suggests that it may play a role in promoting virus egress, as
the pUL37 protein of herpesvirus can interact with dystonin,
an important cytoskeleton cross-linker involved in microtubule-
based transport, in order to promote capsid transport on
microtubules during egress (Pasdeloup et al., 2013). Besides
cellular proteins, VP13 has been shown to interact with viral
helicase, PCP and methytransferase from HEV ORF1, which
suggests a regulatory function for VP13 in orchestrating the
formation of the replicase complex (Osterman et al., 2015).
More interestingly, another study using monoclonal antibody
against VP13 to capture HEV particles showed that VP13 can
associate with virions and support virus release (Takahashi et al.,
2008). The requirement of VP13 for virion release was later
confirmed by a cell culture-adapted genotype 3 HEV strain
with VP13 deletion (Yamada et al., 2009). Studies in Caco-
2 cells and Huh7 cells for the Sar55, a genotype 1 HEV
strain, showed that the intact PSAP motif spanning aa 96–99
in VP13 is required for virion release (Emerson et al., 2010;
Nagashima et al., 2011b). For avian HEV, the PSAP motif in
VP13 has also been found to play a role in virus release (Kenney
et al., 2012). The PSAP motif in VP13 is required for the
formation of membrane-associated HEV particles with the VP13
protein itself associated with lipids. This process is mediated
by the cellular Tsg101 protein (Nagashima et al., 2011a,b).
Replacement of the VP13 PSAP motif with heterologous late
domain motifs (PPPY, YPDL, and PSAA) affects the virus release
(Kenney et al., 2015). The specific interaction between VP13 and
Tsg101 as well as involvement of endosomal sorting complex
required for transport (ESCRT), which commonly participates
in budding of many enveloped viruses, leads to the biogenesis of
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membrane-associated, “quasi-enveloped” HEV particles (Hurley,
2010; Feng et al., 2014; Nagashima et al., 2014; Yin et al., 2016).
Therefore, VP13 is associated with virion during egress and
anti-VP13 antibodies are able to capture HEV virions from
the serum and cell culture supernatant, but not fecal samples
from patients (Takahashi et al., 2008). A possible explanation
is that viral particles could lose lipid-associated VP13 after
passing through the gut (Takahashi et al., 2008). The role of
VP13 in virus release may be one of its functions during
HEV replication in vivo, indispensable for viral spread during
infection.
On the other hand, as a small phosphorylated protein, VP13
can be phosphorylated at Ser71 by MAPK when expressed in
COS1 and Huh7 cells (Zafrullah et al., 1997). A later study
indicates that the Ser71 phosphorylation site is required for
the interaction of the capsid protein and VP13 as VP13 can
interact with the capsid protein in a yeast two-hybrid screen,
especially for the non-glycosylated capsid protein (Tyagi et al.,
2002). This finding also supports a role for VP13 in HEV
structural assembly. However, a mutagenesis study shows that
HEV lacking the phosphorylation site in VP13 is able to replicate
its genome in cultured cells, and to infect rhesus monkeys
similarly to wild type HEV in viremia and seroconversion (Graff
et al., 2005). These data suggest that phosphorylation of VP13
is not necessary for genome replication or for the production
of infectious virions. Moreover, in addition to phosphorylation
and interaction with the capsid protein, VP13 can form a
homodimer via the 43 aa domain located in the C-terminus
(Tyagi et al., 2001b). On the other hand, VP13 has been reported
to activate MAPK-JNK1/2 in hepatoma cells (Parvez and Al-
Dosari, 2015).
Besides the functions mentioned above, VP13 also plays
a role in the interferon induction and signaling. Data from
our laboratory show that VP13 is able to enhance RIG-I
activation, which leads to enhanced RIG-I signaling (Nan et al.,
2014a). The VP13 extends RIG-I half-life and interacts with the
N-terminal portion of RIG-I to enhance its activation by polyI:C.
Interestingly, there is a genotype difference in the enhancement
of RIG-I: genotypes 1 and 3 VP13 but not genotypes 2 and 4
VP13 have the role, implicating that VP13 may relate to HEV
virulence and pathogenesis. On the other hand, another study
demonstrate that VP13 of a genotype 3 HEV strain is able
to interact with the STAT1 (signal transducer and activator of
transcription) to inhibit interferon-α mediated signaling in A549
(human lung adenocarcinoma epithelial cell line; Dong et al.,
2012).
In summary, as the product of the smallest ORF of HEV,
VP13 has multiple functions and plays an indispensable role in
infectivity in experimentally infected animal models. However, it
is not required for HEV replication in cultured cells. Our current
knowledge indicates that VP13 is a multifunctional protein in
interacting with many cellular proteins, modulating host gene
expression and involved in virion release.
Novel ORF4 from Genotype 1 HEV
Recently, a novel ORF4 (nt 2835–3308) was identified from
genotype 1 HEV (Nair et al., 2016). Unlike other ORFs in
HEV, translation of ORF4 is driven by an IRES-like sequence
located in nt 2701–2787 of HEV genome (Nair et al., 2016). The
ORF4 product interacts with multiple viral proteins to form a
protein complex consisting of viral RdRp, helicase and X, and
the ORF4 product stimulated viral RdRp activity to promote
viral replication. Expression of the ORF4 was verified in a cell-
free system and antibodies against this protein were determined
from HEV-infected patients (Nair et al., 2016). However, analysis
of HEV sequences from other genotypes suggests ORF4 is
not conserved across genotypes (Nair et al., 2016). Therefore,
more investigation is needed to elucidate the exact function of
ORF4.
REPLICATION CYCLE OF HEV
Due to the lack of an effective in vitro cell culture system
for HEV, the replication cycle of HEV is largely unknown.
The capsid protein is believed to bind to an unidentified
cellular receptor to initiate viral entry. HEV-VLPs generated
from recombinant ORF2 protein attach to cells via heparin
sulfate proteoglycans (HSPGs; Kalia et al., 2009). Moreover, one
study based on a viral overlay protein binding assay (VOPBA)
suggests that a protein with molecular weight about 55 kDa
could be the candidate receptor for HEV entry; but mass
spectrometry revealed that this virus binding band contained 31
different proteins (Zhang et al., 2011). Another study suggests
that aa 458–607 located in the C-terminal region of the capsid
protein (M domain) may be the putative receptor binding
site of HEV virions (He et al., 2008). Moreover, structure
and sequence analyses suggest that the putative binding motif
of the capsid protein is conserved among all four major
mammalian HEV genotypes (Guu et al., 2009). Heat shock
cognate protein 70 (HSC70), HSPGs and Grp78 are found to
be involved in either cell surface binding with HEV capsids
or intra-cellular transport in different models and are potential
cellular receptors or essential factors for HEV proliferation (Kalia
et al., 2009; Yu et al., 2011; Cao and Meng, 2012). However,
further investigation is needed to confirm if these molecules
truly act as receptors for HEV. After binding with its receptor,
HEV particles are internalized via a dynamin-2, clathrin, and
membrane cholesterol-dependent pathway (Kapur et al., 2012;
Holla et al., 2015). In addition, a recent report suggests the quasi-
enveloped HEV particles enter cells via a distinct pathway that
involves in degradation of the lipid membrane in the lysosome
(Yin et al., 2016).
After entry into permissive cells, the HEV capsid is uncoated
by unknown mechanisms. In one study utilizing VLP from the
truncated capsid protein HEV239, an HSP90-specific inhibitor
(geldanamycin) blocks the intracellular transport of the HEV239
VLP without affecting its entry (Zheng et al., 2010). This suggests
that HSP90 may play a role in the intracellular transport of HEV
particles. After uncoating, the HEV ORF1 translation is followed.
HEV genomic RNA replication relies on the replicase encoded
by ORF1. Along with the generation of the sub-genomic RNA,
translation of ORF2 and ORF3 occurs, followed by virion packing
and egress. For the release of HEV particles, multivesicular body
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(MVB) pathway and ESCRT machinery in the cytoplasm are used
(Nagashima et al., 2014).
CELL CULTURE SYSTEMS AND
PROPAGATION OF HEV
Since the discovery of HEV, many efforts have been made to
develop a rigorous in vitro cell culture system. However, the cell
culture system of HEV is still limited and relatively ineffective,
especially for genotype 1 HEV. An early study tried to use
primary hepatocytes from macaques with serum-free medium for
HEV propagation; however, HEV replication was limited and the
detection of HEV in the medium relied on PCR amplification
(Tam et al., 1996). A group from Japan reports that HEV isolate
87A is able to replicate in A549 cells; however, PCR was also
used to detect viral RNA in the cell culture supernatant (Huang
et al., 1995), instead of immunofluorescence assay to detect viral
proteins. Another group also showed that the A549 cell line could
be used effectively for passaging two Chinese HEV isolates (Wei
et al., 2000).
On the other hand, as the commonly employed method
for single-stranded, positive-sense RNA virus, transfection of
capped RNA from an HEV cDNA infectious clone via in vitro
transcription to PLC/PRF/5 (hepatocellular carcinoma) and
Huh7 cells demonstrates limited replication of HEV (Emerson
et al., 2004). Although cell lysates from the RNA transfected
cells is infectious in rhesus monkeys, cell to cell spread of the
virus in cultured cells is not observed (Emerson et al., 2004).
S10-3 cell line, a subclone of Huh7 hepatoma cell line, has
improved replication efficiency of HEV for the Sar55 strain
(Graff et al., 2006; Shukla et al., 2011). But this assay still
relies on transfection of the cells with full length HEV RNA.
A recent report suggests that replication efficiency of genotype
1 HEV in human hepatoma cell lines (Huh7, Huh7.5, and
HepG2/C3A) is affected by innate immune response (Devhare
et al., 2016).
A Japanese group reports that a genotype 3 isolate from
acute hepatitis patient propagates in PLC/PRF/5 and A549
cells (Tanaka et al., 2007; Okamoto, 2011). After A549 cells
were seeded in a six-well plate and inoculated with HEV at
1.0× 104 and 1.0× 105 RNA copies per well, HEV RNA reached
the highest titer of 107 copies/ml at 50 days post-inoculation.
However, PLC/PRF/5 cells could only support efficient growth
as A549 with a higher MOI (1.0 × 105 viral RNA copies per
well). Moreover, in this HEV cell culture system, HEV infected
cells need to be maintained at 35.5◦C and cultured with a mixed
cell culture medium (50% Dulbecco’s Modified Eagle Medium
and 50% Medium 199) supplemented with 2% (v/v) fetal bovine
serum and 30 mM MgCl2. The same group also reports that a
genotype 4 HEV from a fulminant hepatitis patient can grow
in PLC/PRF/5 and A549 cells and reach a titer of 1.3 × 107
copies/ml within 10–20 days incubation period (Tanaka et al.,
2009). Moreover, a human hepatoma-derived cell line HepaRG
and a porcine embryonic stem cell-derived cell line PICM-19,
which have morphological and functional properties similar to
primary hepatocytes, were shown to support HEV replication
(Rogee et al., 2013). However, the HEV replication level in these
two cell lines is very low and requires 1 month incubation (Rogee
et al., 2013).
In HEV Kernow-C1 p6 cell culture system, the recombinant
virus with human S17 gene insertion was presumed as a minor
species in the host but was selectively adapted to cells after six
passages (Shukla et al., 2011). Replication of Kernow-C1 p6 is
7.5-fold higher in HepG2/C3A human hepatoma cells than in
Huh7.5, PLC/PRF/5, A549, Caco-2 or rhesus kidney cells in a
7-day incubation period, suggesting that HepG2/C3A cell line
is the most permissive. Moreover, this HEV isolate is also able
to infect a variety of non-primate cells, including cow, mouse,
chicken, cat, dog, and rabbit cells, albeit with lower efficiency.
Although it is still unclear how the insertion of S17 occurred
in HEV infected patient, Okamoto’s group demonstrated that
two cell adapted HEV strains HEV JE03-1760F (genotype 3) and
HEV JF5/15F (genotype 4) did not shown any recombination
with cellular S17 gene after 53 and 33 generations of passages
in PLC/PRF/5 and A549 cells, respectively (Okamoto, 2013),
which suggested the recombination and insertion of S17 may
occur in patients rather than in cultured cell. Besides human
HEV isolates, animal HEV strains from domestic pigs, wild boars,
rabbits, and rats can be propagated in human hepatoma cell
lines as well (Jirintai et al., 2012, 2014; Takahashi et al., 2012).
A recent report demonstrates that pluripotent stem cell derived
hepatocytes support HEV replication in vitro (Helsen et al., 2016).
In summary, the current cell culture systems for HEV have
limitations. So far, only one report shows limited replication of a
genotype 1 HEV strain from serum sample in cell culture without
RNA transfection (Takahashi et al., 2010). On the other hand,
although several groups have demonstrated that genotypes 3 or
4 HEV strains can be adapted to cultured cells and are able to re-
infect new cells, a long incubation time is needed in comparison
to other RNA viruses with good cell culture systems. Moreover,
the cell culture adapted Kernow-C1 virus may have a different
phenotype compared with its parental wild type virus as this cell
culture adapted virus contains host gene sequence.
EPIDEMIOLOGY OF HEV
The HEV is primarily transmitted via fecal-oral route. The
most common source of infection is contaminated drinking
water in developing countries. For a long time, hepatitis E was
thought to be a public health problem only for developing
countries. However, hepatitis E is now frequently recognized in
industrialized countries where it was not thought to be endemic
previously (Kwo et al., 1997; Erker et al., 1999; Schlauder et al.,
1999; Worm et al., 2000; Kabrane-Lazizi et al., 2001; Mizuo et al.,
2002; Sadler et al., 2006).
World Health Organization estimates that there are 20 million
HEV infections annually across the world. Among these cases,
there are over 3 million symptomatic cases and 56,600 deaths
(WHO, 2015). Hepatitis E is highly endemic in East and South
Asia. Data indicates over 50% of global hepatitis E deaths occur
in this region. In East Asia, large outbreaks of hepatitis E have
only been described in China. Hepatitis E accounts for 20–50%
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of acute hepatitis cases in this region. The seroprevalence of anti-
HEV antibodies in the region varies from 10 to 50%, indicating
that hepatitis E is hyperendemic in this region. In South Asia,
outbreaks of hepatitis E have been reported in most countries
in this region, but variable in scale (WHO, 2015). HEV accounts
for 20–60% of sporadic acute hepatitis and fulminant liver failure
in this region. In particular, the rates of fulminant liver failure
are usually higher in pregnant patients. A recent paper reported
that HEV infection causes 49% acute viral hepatitis and 75%
fulminant hepatic failure in pregnant women in one area in India
(Kumar et al., 2014). However, the seroprevalence rates of prior
exposure to HEV are relatively low, ranging from 10 to 40% in
most studies.
In the developed countries, such as North America, Western
Europe and Japan, no outbreaks have been reported. These
areas are considered as low or non-endemic for HEV. However,
sporadic cases of hepatitis E have been reported. Transmission
of HEV from animal reservoirs to humans is assumed to be
the major cause of those sporadic cases. A series of cases of
HEV infection in people who ate undercooked deer meat 6–
7 weeks before the onset of disease have been reported (Tei
et al., 2003; Yazaki et al., 2003; Li et al., 2005c). HEV RNA
recovered from the leftover deer meat was found to be identical
in sequence to the HEV RNA recovered from the patients
(Takahashi et al., 2004). Consumption of shellfish is considered
a risk factor in a documented case (Koizumi et al., 2004).
Thus, foodborne infection may occur from the consumption
of uncooked/undercooked products from infected animals.
Moreover, blood transfusion and solid organ transplant mediated
HEV transmission are reported (Pas et al., 2012; Wedemeyer
et al., 2012; Sue et al., 2016). IgM and IgG against HEV are
detected in recipients of blood transfusions (Wedemeyer et al.,
2012).
Hepatitis E virus genotype 1 is responsible for most endemic
and epidemic cases of hepatitis E in Asia, and genotype 2 is
prevalent in Central America and Africa (Purcell and Emerson,
2008). There is no known animal reservoir for HEV genotypes 1
and 2 (Wedemeyer et al., 2012). Genotypes 3 and 4 are zoonotic
and can cause HEV infections in the developed countries. For the
detailed geographical distribution of hepatitis E virus genotypes,
please refer to these reviews (Dalton et al., 2008; Kamar et al.,
2012a).
PATHOGENESIS, CLINICAL SIGNS, AND
DIAGNOSIS OF HEV INFECTION
Hepatitis E virus infection mainly causes acute hepatitis with
a case fatality rate from 0.5 to 3% in young adults (Jameel,
1999). Remarkably, case fatality rate resulting from HEV-related
fulminant liver failure can reach up to 30% in infected pregnant
women in their third trimester of gestation (Jameel, 1999).
Generally, HEV has an incubation period of 2–8 weeks (Purcell
and Emerson, 2008). The initial symptoms of acute hepatitis E are
unspecific and flu-like, such as myalgia, arthralgia, and weakness.
After this short prodromal phase, a period of symptoms such as
vomiting, itching, uncolored stools, darkened urine and jaundice
could last for days to several weeks accompanied by increased
levels of liver transaminases, bilirubin, alkaline phosphatase, and
γ-glutamyltransferase (Hoofnagle et al., 2012; Wedemeyer et al.,
2012). Current case reports indicate that most cases are self-
limited and do not result in chronic hepatitis (Hoofnagle et al.,
2012). An investigation on pregnancy outcomes in hepatitis E
shows higher HEV loads in pregnant women with acute viral
hepatitis and fulminant hepatic failure, and higher levels of
TNF-α, IL-6, IFN-γ, and TGF-β1 than non-pregnant women,
which suggests that high cytokine levels are correlated with severe
liver injury in HEV infection (Kumar et al., 2014). A recent study
highlights the role of TLR3 and IFN-γ in HEV pathogenesis.
Patients with high levels of TLR3 and robust IFN-γ response
are observed in self-limiting acute viral hepatitis cases, and are
able to limit the disease and recover uneventfully (Majumdar
et al., 2015). However, patients with lower expression of TLR3
and IFN-γ progress to acute liver failure (Majumdar et al.,
2015).
HEV can cause chronic infection as well. Although chronic
HEV infection was initially reported only in immuno-
compromised persons, such as organ transplant recipients,
patients receiving cancer chemotherapy and HIV-infected
persons (Hoofnagle et al., 2012), latest reports show that chronic
HEV infection also occurs in an immunocompetent individual
with systemic lupus erythematosus (SLE; Grewal et al., 2014).
However, since this kind of cases are rare, data available so far are
not sufficient to consider this patient as an immunocompetent
individual (Kamar and Izopet, 2014). In organ transplant
recipients, the chronic course leads to persistent increases
in levels of alanine aminotransferase, significant histological
activity and fibrosis in some cases (Wedemeyer et al., 2012).
HIV-infected individuals have higher positive rate of anti-HEV
antibody than individuals without HIV infection (Wedemeyer
et al., 2012).
Besides hepatitis, extrahepatic manifestations have been
documented. Neurological disorders, such as polyradiculopathy,
Guillain–Barré syndrome, bilateral brachial neuritis, encephalitis
and proximal myopathy, and neuralgic amyotrophy are reported
in patients with acute and chronic HEV infections (Kamar et al.,
2011, 2014; van den Berg et al., 2014; van Eijk et al., 2014; Dalton
et al., 2016; Drave et al., 2016). The kidney injury caused by HEV
infection is reported and also documented in monkeys infected
experimentally with HEV as well (Kamar et al., 2005, 2012b;
Geng et al., 2016). Furthermore, a recent report provides evidence
that extrahepatic replication of HEV in the placenta of infected
mothers, which may be associated with fetal mortality (Bose et al.,
2014). It also raises the concern for the vertical transmission of
HEV to fetus and newborn by an infected mother (Krain et al.,
2014).
A report suggests the association between the outcome of
HEV infection in solid-organ transplant patients and the genetic
heterogeneity of HEV quasispecies in ORF1 (Lhomme et al.,
2014). Analysis of the viral genetic heterogeneity indicates that
both nucleotide complexity and genetic distance of the ORF1
proline-rich domain in patients whose infection became chronic
are higher than the patients who cleared the virus (Lhomme et al.,
2014).
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Although diagnostic tests for HEV are commercially available,
none of them have been formally approved in the United States by
the Food and Drug Administration (FDA; Hoofnagle et al., 2012).
Current tests mainly target anti-HEV antibodies, including IgG
and IgM. However, several assays are based on antigens expressed
by a single HEV genotype, especially genotype 3, and might be
limited for the detection of all HEV genotypes. Indeed, there are
variations in sensitivity, specificity and agreement in the results
of these assays, which may account for the discrepancies among
positive rates of anti-HEV antibodies in various populations
(Mast et al., 1998; Herremans et al., 2007; Drobeniuc et al.,
2010). It is also notable that a recent study demonstrates the false
positive result in HEV IgM test due to cross reaction with EBV
and CMV, which heavily affects the accuracy of HEV serology
testing (Hyams et al., 2014). Only 13.3% of the total samples with
the positive HEV IgM were PCR positive for HEV RNA. The cross
reactivity of IgM against HEV, EBV, and CMV is very high. These
data suggest that to confirm HEV infection in patients, clinical
features, blood ALT level and PCR testing should be all included
in addition to serological test alone.
On the other hand, although HEV RNA can also be detected
in blood and stool for several weeks after acute HEV infection, in
addition to a narrow detectable window of HEV viremia (Hyams
et al., 2014), current HEV RNA tests are still experimental since
they have not been standardized yet (Wedemeyer et al., 2012).
Furthermore, diagnostic support for IgM and IgG anti-HEV
detection in clinical samples using commercially available kits
and PCR assay for detection of HEV RNA in serum and stool
samples are also available from the Division of Viral Hepatitis in
the Centers for Disease Control and Prevention (CDC, 2016).
TREATMENT AND PREVENTION OF HEV
INFECTION
Hepatitis E virus infection mainly causes a self-limited disease
and most infected individuals are able to clear it spontaneously.
Although the case fatality rate in adults is 0.5–3%, the rate
can increase to 30% in pregnant women during their third
trimester of gestation in South Asia (Jameel, 1999). Therefore,
antiviral therapy is needed. Although no specific treatment has
been approved for HEV, off-label application of ribavirin as
monotherapy for HEV has demonstrated promising results in
both acute and chronic hepatitis E patients (Kamar et al., 2010;
Mallet et al., 2010; Gerolami et al., 2011). In vitro assay showed
that ribavirin could inhibit replication of genotypes 1–3 HEV
through the depletion of intracellular GTP pools in HEV infected
cells (Debing et al., 2014a). For immunosuppressed patients,
a reduction of immunosuppression has shown efficacy in the
treatment of chronic HEV infection (Wedemeyer et al., 2012).
Moreover, application of pegylated interferon in combination
with ribavirin has been reported as a treatment for chronic
HEV infection but only shown moderately synergistic effect
(Wedemeyer et al., 2012; Debing et al., 2014a). However, due to
the evidence of embryolethality and teratogenicity revealed by
animal study, ribavirin has been assigned to pregnancy category
X by the FDA and contraindicated in women who are pregnant
and in the male partners of women who are pregnant (Sayed
et al., 2015). Moreover, ribavirin-induced G1634R mutation
was reported and associated with treatment failure of ribavirin
monotherapy in solid-organ transplant patients (Debing et al.,
2014b; Lhomme et al., 2015; Todt et al., 2016). Therefore, viral
specific treatment for HEV is needed.
Our laboratory has successfully tested application of peptide-
conjugated morpholino oligomers (PPMOs) as novel anti-HEV
compounds (Nan et al., 2015). PPMOs are water soluble,
nuclease-resistant single-stranded DNA analogs containing a
backbone of morpholine rings and phosphorodiamidate linkages
along with conjugation of arginine-rich cell penetrating peptide
for facilitating cell delivery (Summerton, 1999; Abes et al., 2006).
PPMOs bind to mRNA by Watson–Crick base pairing and
interfere with translation through steric blockade of the AUG-
translation initiating region. Antisense morpholino oligomers are
currently tested in clinical trials for treating Duchenne muscular
dystrophy in humans and has been documented as effective
against numerous types of viral infections in experimental
animal models (Anthony et al., 2012; Mendell et al., 2013;
Moulton, 2013). Importantly, upon systemic administration,
PPMOs distribute to liver, remain pharmacologically viable, and
are effective at reducing viral titers (Amantana et al., 2007; Burrer
et al., 2007; Paessler et al., 2008). In our study, PPMO HP1
targeting 5′ UTR of HEV genotype 1 Sar55 strain demonstrates
strong inhibition of HEV replication (Nan et al., 2015). Since the
5′ UTR of HEV genome is highly conserved among different HEV
genotypes infecting humans, the PPMO HP1 may be an HEV-
specific inhibitor with antiviral activity across multiple HEV
genotypes (Nan et al., 2015). These qualities, along with the
in vitro efficacy against HEV (Nan et al., 2015), make PPMOs
be appealing for consideration as a novel inhibitor of HEV
infections.
Another nucleic-acid based strategy, siRNA, has also been
reported to be effective in inhibiting HEV replication. An siRNA
targeting HEV RdRp was reported to inhibit HEV replication in
A549 cells and in piglets (Huang et al., 2009). In another report,
siRNA targeting a 3′ cis-acting element and viral nucleotide
sequences coding for helicase and RdRp are effective against HEV
in HepG2 cells (Kumar et al., 2010). However, it is generally
acknowledged that siRNA needs considerable improvements in
their delivery to relevant targets in vivo before they can be
considered for clinical applications involving systemic delivery
against virus infections.
Current prevention for HEV relies on sanitary measures, such
as providing clean water, and appropriately cooked food to avoid
transmission from undercooked food (Kamar et al., 2012a). Since
in vitro culturing of HEV is limited and ineffective, HEV vaccine
development mainly focuses on the expression of the capsid
protein as a subunit vaccine. The capsid protein shares over 85%
identity among the four major HEV genotypes in mammalian
hosts (Mori and Matsuura, 2011). The capsid protein from
genotype 1 HEV expressed by baculovirus or bacterial vectors has
been tested in clinical trials. The first candidate was a 56 kDa
protein expressed in insect cells. In a phase 2 trial in Nepal,
the vaccine is well-tolerated and highly immunogenic, with 95%
efficacy for protection against hepatitis E (Shrestha et al., 2007).
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The second vaccine, HEV239, encompasses aa 368–606 of ORF2
product, is a 26 kDa truncated protein expressed in E. coli (Li
et al., 2005b). This vaccine is well-tolerated with an efficacy
of 100% protection after three doses in a population tested in
China, which included both men and women aged 16–65 years
(Zhu et al., 2010). The HEV239 vaccine was approved and
marketed in China in 2012. Whether it will be endorsed in other
countries or how effective it is against all other genotypes of HEV
infecting humans remains unknown. Moreover, a study shows
that HEV239 vaccine could protect rabbits against homologous
and heterologous HEV challenge (Liu et al., 2014; Zhang et al.,
2015). A recent report demonstrates that a hybrid protein
fusing protruding (P) domains from capsid proteins of both
Norovirus (NoV) and HEV induces a higher antibody titer than
either P domain alone (Wang et al., 2014a). Subunit vaccine
candidates containing antigens of HEV, rotavirus, and astrovirus
are reported as well (Xia et al., 2016).
CONCLUSION AND PERSPECTIVES
More than 20 years have passed since the discovery and complete
genome sequencing of HEV. Our understanding of HEV is still
limited, though ongoing research continues to reveal more and
more information about this virus. Currently, we know that HEV
is not only a public health concern in developing countries as
previously thought, but also a concern with a more complicated
scenario in the developed countries. More and more animal
reservoirs are revealed and we now understand that genotypes
3 and 4 HEV are zoonotic and foodborne pathogens. However,
the cross-species transmission and host tropism of different
HEV genotypes are still elusive. Current data imply certain viral
proteins such as ORF1 product plays a role in the host tropism
of HEV. Further investigation is needed to elucidate the basic
biology of HEV.
On the one hand, although approved in China, the HEV239
vaccine is still unavailable to most of the world, despite the
fact that serum surveillance indicates a high prevalence rate of
HEV throughout the world. Moreover, recent discoveries about
the antigenicity variation between HEV genotypes and quasi-
enveloped viral particles hidden from neutralizing antibody
suggest new challenges and questions about the efficacy of the
approved vaccine. Further investigation about the vaccine efficacy
against multiple HEV genotypes or seeking for an improved
vaccine is needed. In addition, virus specific treatment for HEV
infection is not available yet. Although, the off-label using of
pegylated IFNs and antiviral drugs for general purposes have
demonstrated efficacy against HEV, safety is still a concern
as no validation has yet been conducted for these treatments.
Therefore, a HEV-specific treatment such as PPMOs is needed.
Due to the absence of a suitable animal model and a simple cell
culture system, many details about this virus and its infection,
such as its biology, pathogenesis, strain variances, genotype
differences, molecular mechanisms and vaccine efficacy for cross
protection are still incomplete. However, current information
also indicates that it is possible to establish a useful cell culture
system using certain HEV strains such as the cell culture-adapted
Kernow-C1 strain. These recent advances will facilitate further
studies, which hopefully will reveal more insights about the basic
biology of HEV, such as proteolytic processing of ORF1 product,
functions of the viral proteins, HEV pathogenesis, effective
therapeutics and a better vaccine.
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